COMTREX Acute Head Cold (Panadol Acute Head Cold) – Paracetamol, Pseudoephedrine & Brompheniramine for Cold and Flu Symptoms
COMTREX® Acute Head Cold
1. Disclaimer
This commentary is intended for general educational and pharmaceutical-information purposes only. It is not a substitute for the current package leaflet, prescribing information, or individualized advice from a physician or pharmacist. Product names, formulations, manufacturers, marketing authorization arrangements, pack sizes, and labeling may change between markets and over time; therefore, the information below should be interpreted in the context of the Egyptian product identified in the available current sources.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
2. Summary
COMTREX® Acute Head Cold is a multi-ingredient oral medicine intended for the short-term symptomatic relief of common-cold and influenza-associated symptoms. Its Egyptian formulation contains three active ingredients: acetaminophen (paracetamol) 500 mg, pseudoephedrine hydrochloride 30 mg, and brompheniramine maleate 2 mg per film-coated tablet. The combination provides analgesic/antipyretic, nasal-decongestant, and antihistaminic actions, respectively.
An important current Egyptian-market update is that the product formerly marketed as Comtrex Acute Head Cold has been renamed/repositioned as Panadol Acute Head Cold. Haleon’s Egypt healthcare-professional website currently lists Panadol Acute Head Cold as a nonprescription triple combination of paracetamol, pseudoephedrine HCl, and brompheniramine maleate.
The medicine treats symptoms rather than the underlying viral infection; pseudoephedrine, for example, relieves congestion but does not treat its cause or shorten the illness.
3. Brand Name
Historical Egyptian brand: COMTREX® Acute Head Cold.
Current Egyptian-market name: Panadol® Acute Head Cold.
Current Egyptian healthcare-professional information from Haleon identifies Panadol Acute Head Cold as the corresponding triple combination containing paracetamol, pseudoephedrine HCl, and brompheniramine maleate. Egyptian pharmacy listings likewise identify Panadol Acute Head Cold as the former Comtrex product.
4. Category
Therapeutic category: Cold and flu symptomatic treatment.
Pharmacological components:
- Analgesic and antipyretic: acetaminophen/paracetamol.
- Nasal decongestant/sympathomimetic: pseudoephedrine.
- First-generation H1 antihistamine: brompheniramine.
The combination therefore addresses several cold/flu symptoms simultaneously rather than acting as an antimicrobial treatment.
5. Active Ingredient
Each film-coated tablet contains:
- Acetaminophen (Paracetamol): 500 mg
- Pseudoephedrine hydrochloride: 30 mg
- Brompheniramine maleate: 2 mg
These strengths are documented for Egyptian-market Comtrex/Panadol Acute Head Cold products and are consistent with published analytical work performed on locally marketed Comtrex tablets.
6. Pharmaceutical Form & Strength
Dosage form: Oral film-coated tablet/caplet.
Strength per tablet: acetaminophen 500 mg + pseudoephedrine HCl 30 mg + brompheniramine maleate 2 mg.
Current Egyptian pharmacy listings identify the marketed presentation as 20 film-coated tablets.
The older description of a 10-caplet box should therefore not be treated as the current Egyptian presentation; current Egyptian listings consistently identify a 20-tablet presentation.
7. Manufacturer & Marketing Authorization Holder
Historical Egyptian documentation and a peer-reviewed analytical study identify the locally marketed Comtrex tablets as manufactured by GlaxoSmithKline Egypt for Novartis Pharma Egypt, under license from Novartis Consumer Health, Switzerland.
For the current Egyptian product, the official Egyptian Haleon healthcare-professional website lists Panadol Acute Head Cold and states that the site is operated by Haleon EG Limited. However, the currently accessible page does not provide sufficient evidence to assign a present-day Egyptian manufacturing site or marketing-authorization-holder designation for this particular product with the same degree of certainty as the historical Comtrex documentation. Accordingly, a current MAH/manufacturer should be verified directly from the latest Egyptian package and official product leaflet rather than inferred from the historical Comtrex labeling.
8. Mechanism of Action
The three ingredients act through different mechanisms:
Acetaminophen (paracetamol): produces analgesic and antipyretic effects, principally through suppression of prostaglandin-mediated pain and temperature pathways. It is not considered a conventional NSAID and has little clinically significant peripheral anti-inflammatory activity.
Pseudoephedrine: is a sympathomimetic nasal decongestant. Its vasoconstrictor effect on the nasal mucosa reduces vascular swelling and thereby improves nasal obstruction and sinus congestion/pressure.
Brompheniramine: is a first-generation H1-antihistamine that blocks histamine-mediated symptoms such as sneezing and rhinorrhea. Because it is a first-generation antihistamine, central nervous system effects including drowsiness may occur.
9. Spectrum of Activity
This product has no antimicrobial spectrum of activity.
It is a symptomatic cold-and-flu combination, not an antibiotic, antiviral, or antibacterial agent. Its therapeutic effects are directed against symptoms such as pain, fever, nasal congestion, rhinorrhea, and sneezing rather than against the causative organism.
10. Pharmacokinetics
The exact pharmacokinetic profile of the commercial three-drug tablet should ideally be taken from the product-specific regulatory dossier; detailed current Egyptian product-specific PK labeling was not identified in the publicly accessible sources. The following describes the established pharmacokinetic characteristics of the individual active ingredients.
Acetaminophen: is rapidly absorbed following oral administration. Studies of oral tablets have demonstrated peak plasma concentrations within approximately 1 hour, with an elimination half-life generally around 2–3 hours in healthy adults. It is extensively metabolized in the liver, principally by conjugation, with metabolites eliminated mainly through the kidneys.
Pseudoephedrine: is well absorbed orally and is eliminated predominantly through the kidneys. Its elimination is substantially affected by urinary pH, and the typical adult half-life is on the order of several hours. Published pharmacokinetic reviews report approximately 6 hours in adults, with shorter half-lives possible in children.
Brompheniramine: is absorbed after oral administration and has a comparatively long duration of antihistaminic activity. In a study of healthy adults, the mean time to peak serum concentration was approximately 3.1 hours and the mean elimination half-life was approximately 24.9 hours; pharmacokinetic behavior can vary with age and patient characteristics.
11. Indications
The combination is intended for the temporary symptomatic relief of common-cold and influenza-associated symptoms, including:
- Headache.
- Minor aches and pains, including muscular/body aches.
- Fever.
- Sore-throat pain.
- Nasal congestion.
- Sinus congestion and pressure.
- Runny nose and sneezing.
The current Egyptian Haleon information confirms Panadol Acute Head Cold as a nonprescription triple combination for temporary relief of symptoms associated with common cold and flu.
12. Administration
The historical Egyptian Comtrex labeling specifies for adults and children 12 years of age and older: 2 caplets every 6 hours as needed, not exceeding 8 caplets in 24 hours. This corresponds to a maximum of 4,000 mg acetaminophen per 24 hours from this product alone.
Because acetaminophen may also be present in many other prescription and nonprescription medicines, the total acetaminophen exposure from all sources must be considered. The FDA states that adults and children 12 years and older should not exceed 4,000 mg of acetaminophen in 24 hours.
Children under 12 years: the historical Comtrex labeling states not to use the product in this age group. Do not extrapolate the adult combination dose to younger children.
The dosing instructions on the current package/leaflet should take precedence over historical Comtrex wording if the formulation or directions have subsequently been revised.
13. Method of Preparation
No preparation or reconstitution is required.
This is a ready-to-use oral film-coated tablet. The tablet should be swallowed with water according to the product's current dosing instructions.
14. Contraindications
The product should not be used in patients with hypersensitivity to acetaminophen, pseudoephedrine, brompheniramine, or any formulation component.
The pseudoephedrine component also makes the product unsuitable for patients currently receiving a prescription monoamine oxidase inhibitor (MAOI) or who have discontinued an MAOI within the preceding 2 weeks, because of the potential for serious sympathomimetic interactions.
Patients with severe or uncontrolled cardiovascular disease or hypertension, significant hyperthyroidism, clinically important urinary obstruction, glaucoma, or serious hepatic/renal disease require medical assessment before use, and in some circumstances the combination may be inappropriate.
15. Warnings & Precautions
Important precautions include:
Acetaminophen-related hepatotoxicity: Do not combine with other acetaminophen/paracetamol-containing products unless specifically directed by a healthcare professional. Excessive total intake can cause severe liver injury, liver failure, and death.
Cardiovascular effects: Pseudoephedrine may increase blood pressure and heart rate and should be used cautiously in patients with cardiovascular disease or hypertension.
Thyroid disease and diabetes: Sympathomimetic effects may be clinically important in patients with thyroid disease or diabetes; medical advice is appropriate before use.
Glaucoma and urinary difficulty: Brompheniramine has anticholinergic effects, while pseudoephedrine may also aggravate urinary difficulty; caution is required in glaucoma and prostatic enlargement.
Respiratory disease: Patients with conditions such as emphysema or chronic bronchitis should seek professional advice before using brompheniramine-containing products.
Drowsiness and impaired alertness: Brompheniramine may cause drowsiness. Driving, operating machinery, or performing hazardous activities should be avoided or undertaken only with appropriate caution until the individual's response is known.
Alcohol and sedatives: Alcohol, sedatives, and tranquilizers may increase central nervous system depression and impairment associated with first-generation antihistamines. Alcohol should therefore be avoided.
MAOI interaction: Do not use with a prescription MAOI or within 14 days after stopping one.
Duration of self-treatment: The older Comtrex wording stated a 7-day limit, but an exact current Egyptian duration was not confirmed from the accessible official manufacturer page. A professional should therefore be consulted if symptoms fail to improve promptly, worsen, recur, or are accompanied by significant fever or other concerning symptoms, and the current leaflet should be followed for the authorized duration of use. The established pseudoephedrine OTC labeling advises medical assessment when symptoms do not improve within 7 days or occur with fever.
16. Drug Interactions
Important interaction considerations include:
MAO inhibitors: contraindicated with pseudoephedrine-containing products during treatment and for 14 days after discontinuation of the MAOI.
Other acetaminophen-containing medicines: concurrent use can unintentionally exceed the maximum daily acetaminophen exposure and increase the risk of hepatotoxicity.
Sedatives and tranquilizers: may increase drowsiness and psychomotor impairment caused by brompheniramine.
Alcohol: can increase CNS impairment associated with brompheniramine and may increase the risk of acetaminophen-related liver toxicity with excessive or chronic alcohol consumption.
Other sympathomimetics/stimulants: may produce additive cardiovascular or CNS stimulation with pseudoephedrine, potentially increasing nervousness, tachycardia, or blood pressure.
Patients taking prescription medicines should therefore have the full medication list reviewed by a pharmacist or physician before use.
17. Side Effects
Potential adverse effects reflect the three active ingredients.
Common or relatively expected effects may include:
- Drowsiness or reduced alertness.
- Dizziness.
- Dry mouth.
- Nervousness or restlessness.
- Difficulty sleeping.
- Nausea or gastrointestinal discomfort.
- Headache.
- Palpitations or increased heart rate.
Brompheniramine can produce antihistaminic and anticholinergic effects such as drowsiness and dry mouth, while pseudoephedrine can cause sympathomimetic symptoms including nervousness, insomnia, palpitations, or increased blood pressure.
Serious adverse effects requiring urgent medical attention can include severe allergic reactions, significant cardiovascular symptoms, severe confusion or marked CNS effects, or evidence of acetaminophen-induced liver injury such as jaundice, dark urine, or upper abdominal pain.
18. Use in Special Populations
Children: The historical Egyptian Comtrex labeling specifies use for patients 12 years and older and not for children under 12. Adult combination dosing should not be applied to younger children.
Older adults: Greater caution may be appropriate because of increased susceptibility to anticholinergic effects, CNS effects, urinary retention, cardiovascular effects, and age-related hepatic or renal impairment.
Pregnancy: Use should be based on an individualized risk-benefit assessment with a healthcare professional. The product should not be self-selected during pregnancy simply because individual components may be available OTC.
Breastfeeding: Professional advice is recommended before use because the components may pass into breast milk and because the combined product exposes the infant to multiple active substances.
Hepatic impairment: Particular caution is warranted because acetaminophen is extensively metabolized in the liver and excessive exposure can cause severe hepatotoxicity.
Renal impairment: Pseudoephedrine is predominantly renally eliminated, and renal impairment can alter exposure; caution and professional assessment may therefore be required.
19. Storage Conditions
The historical Egyptian labeling specifies storage below 30°C, protected from excessive heat and light.
Because storage instructions may differ between current presentations, the temperature and handling requirements printed on the current package/leaflet should be followed as the controlling information.
Keep out of the reach of children.
20. Additional Sections
Overdose
Overdose is particularly important because the product contains acetaminophen. Excessive acetaminophen exposure may produce potentially fatal hepatic injury, even when the patient initially feels well. Immediate medical evaluation is recommended after suspected overdose rather than waiting for symptoms to appear.
N-acetylcysteine (NAC) is the established antidotal treatment for acetaminophen poisoning and is most effective when administered promptly under medical supervision. It is therefore more accurate to describe N-acetylcysteine rather than simply “acetylcysteine as an antidote” without context.
Therapeutic role
The combination is intended for patients who have multiple cold/flu symptoms requiring different types of symptomatic treatment. It is not necessary to take a combination product when only one symptom requires treatment, particularly where doing so would unnecessarily expose the patient to additional active ingredients.
21. Frequently Asked Questions (FAQ)
What is Comtrex Acute Head Cold used for?
It is used for temporary relief of multiple common-cold and flu symptoms, including pain, fever, nasal congestion, sinus pressure, runny nose, and sneezing.
Is Comtrex still the current name in Egypt?
The Egyptian product has been marketed under the name Panadol Acute Head Cold; current Haleon Egypt information lists this product with the same three active ingredients.
Does it contain paracetamol?
Yes. Each tablet contains 500 mg acetaminophen (paracetamol) according to documented Egyptian-market product information.
Can it be taken with Panadol or another paracetamol-containing medicine?
Not routinely. Because this product already contains acetaminophen, combining it with another acetaminophen/paracetamol-containing medicine can result in an excessive total daily dose and increase the risk of liver injury.
Can it cause drowsiness?
Yes. Brompheniramine is a first-generation antihistamine and can cause drowsiness and impaired alertness.
Does it cure the common cold or influenza?
No. It provides symptomatic relief; it does not eradicate the underlying viral infection or necessarily shorten the illness.
Can someone with high blood pressure take it?
Pseudoephedrine can raise blood pressure and heart rate. People with hypertension or cardiovascular disease should obtain professional advice before using the product.
Can it be used during pregnancy or breastfeeding?
Pregnant or breastfeeding patients should consult a healthcare professional before use rather than self-medicating with the combination.
What should be done in an overdose?
Seek emergency medical assistance immediately, even if no symptoms are present, because serious acetaminophen toxicity can initially be clinically silent.
22. References
- Haleon HealthPartner Egypt. Paracetamol formulations / Panadol Acute Head Cold. Current Egyptian healthcare-professional information identifying Panadol Acute Head Cold as a paracetamol + pseudoephedrine HCl + brompheniramine maleate combination.
- Haleon HealthPartner Egypt. Panadol Overview / Panadol Product Range. Current Egyptian product-range information.
- Youssef et al., BMC Chemistry (2019). Analytical methods for the determination of paracetamol, pseudoephedrine and brompheniramine in Comtrex tablets. Documents the Egyptian-market Comtrex formulation containing 500 mg paracetamol, 30 mg pseudoephedrine, and 2 mg brompheniramine and the historical manufacturing/licensing arrangement.
- U.S. FDA. Acetaminophen. Current safety information regarding maximum total daily acetaminophen exposure and overdose-related liver injury.
- MedlinePlus / U.S. National Library of Medicine. Acetaminophen Drug Information. Warnings, overdose precautions, use, and adverse effects.
- MedlinePlus / U.S. National Library of Medicine. Pseudoephedrine Drug Information. Mechanism, administration, and general safety information.
- MedlinePlus / U.S. National Library of Medicine. Brompheniramine Drug Information. Antihistaminic mechanism and clinical use.
- DailyMed. Pseudoephedrine Hydrochloride tablet, film coated. Current labeling covering dosing, MAOI precautions, cardiovascular and metabolic warnings, and the 7-day symptom warning.
- DailyMed. Brompheniramine-containing OTC labeling. Current safety information concerning drowsiness, alcohol, sedatives/tranquilizers, glaucoma, urinary difficulty, and respiratory disease.
- Simons FE, Frith EM, Simons KJ. The pharmacokinetics and antihistaminic effects of brompheniramine. Journal of Allergy and Clinical Immunology. 1982;70(6):458–464.
- Kanfer I, et al. Pharmacokinetics of Oral Decongestants. Pharmacotherapy. 1993. Data concerning oral pseudoephedrine disposition and elimination.
- Published acetaminophen pharmacokinetic studies documenting rapid oral absorption and an elimination half-life of approximately 2–3 hours in healthy adults.